Publications & Posters

Publications

2020

Kleen T-O, Galdon AA, MacDonald AS, Dalgleish AG. Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends”. Front. Immunol. 2020. doi: 10.3389/fimmu.2020.02059

2019

Dalgleish AG. Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy? Expert Review of Anticancer Therapy 2019; 19(12):1001–1003.

2018

Dalgleish AG, Mudan S, Fusi A. Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity. J Transl Med 2018. doi.org/10.1186/s12967-018-1602-8

2017

Bazzi S, El-Darzi E, McDowell T et al. Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria. Front. Immunol. 2017. 10.3389/fimmu.2017.01253/full

2017

Bazzi S, Modjtahedi H, Mudan S et al. Immunomodulatory effects of heat-killed Mycobacterium obuense on human blood dendritic cells. Innate Immun 2017; 23(7):592–605.

2016

Dalgleish AG, Stebbing J, Adamson DJ et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 2016; 115(7):789–796.

2016

Dalgleish A. Interview with Professor Angus Dalgleish. Immunotherapy 2016; 8(11):1271–1276.

2015

Dalgleish et al. Pancreatic cancer: latest drug development hits and misses. ASCO Post, February 25, 2015.

2015

Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 2015; 7(3):309–316.

2015

Brunet LR, Hagemann T, Gaya A et al. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? OncoImmunology 2015; 5(4):e1112942.

2013

Elia A, Brunet LR and Hagemann T. William Coley’s legacy – the development of modern mycobacteria-based therapies for cancer. Trends in Cancer Research 2013; (9):109-117.

2012

Stebbing J, Dalgleish A, Gifford-Moore A et al. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Annals of Oncology 2012; 23(5):1314–1319.

2011

Fowler DW, Copier J, Wilson N et al. Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 2011; 61(4):535–547.

2019

Galdon A, Crooks J, Brown S et al. Defining the immunomodulatory effects of IMM‑101:
a promising co-therapy for cancer. Poster presented at the British Society for Immunology Congress held in Liverpool (UK) 2-5 December 2019.

2019

Fusi A, Dalgleish AG. Long-Term Survival of Patients with Stage III/IV Melanoma Receiving IMM-101. Poster presented at the 16th International Congress of the Society for Melanoma Research, held at Salt Lake City, Utah (USA) 20-23 November 2019 and published in Pigment Cell Melanoma Res. 2020;33:148–255.

2019

Dalgleish and the IMAGE 1 Trial Investigators. IMAGE 1 (Immune Modulation and Gemcitabine Evaluation), a Randomised, Open-label Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer (Including results from the long-term follow-up Sub-Study). Poster presented at the Pancreatic Cancer Symposium, Toulouse (France) 23-24 October 2019.

2019

Galdon A, Crooks J, Brown S et al. Defining the immunomodulatory effects of IMM‑101: a promising co-therapy for cancer. Poster presented at CRI-CIMT-EATI-AACR CICON in Paris (France) 25-28 September 2019 and published as A111 in the CICON 2019 Abstracts Book.

2018

Galdon A, Crooks J, Brown S et al. Defining the immunomodulatory effects of IMM‑101: a promising co-therapy for cancer. Poster presented at the 32nd Annual Conference of European Macrophage & Dendritic Cell Society (EMDS) held in Verona (Italy) 27-29 September 2018.

2018

Dalgleish and the IMAGE 1 Trial Investigators. IMAGE 1 (Immune Modulation and Gemcitabine Evaluation), a Randomised, Open-label Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer (Including results from the long-term follow-up Sub-Study). Poster presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in Washington, D.C. (USA) 07–11 November 2018.

2017

Brunet LR, Crooks J, Brown S, et al. The Immunomodulatory Effects of Cancer Therapy on IFN-gamma Responses in the Periphery. Poster presented at the Annual Meeting of SITC, held at National Harbour, Maryland (USA) 10-12 November 2017 and published in Journal for ImmunoTherapy of Cancer 5(Suppl 2):P81.

2017

Cunningham D, Blay JY, Marabelle A, et al. A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry. 2017: Journal of Clinical Oncology 35, no. 15_suppl. 

2017

Rosa Brunet L , Carroll K , Summerton L , et al. Baseline carcinoembryonic antigen predicts response to IMM-101 in advanced pancreatic cancer: Data analysis from a randomised, open label, phase II study. P-192 – Annals of Oncology; Vol 28, Suppl 3, 2017.

2016

Crooks J, Brown S, Gauthier A, et al. The effect of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense (NCTC 13365) on dendritic cells and the adaptive immune response. Poster presented at the British Society for Immunology, held in Liverpool (UK) 6-9 December 2016.

2016

Crooks J, Brown S, Gauthier A, et al. The effect of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense (NCTC 13365) with checkpoint inhibitors in pre-clinical models. Poster presented at the Annual Meeting of SITC, held at National Harbour, Maryland (USA) 9-13 November 2016.

2016

Dalgleish AG, Harries M, Stebbing J & Mudan S. Does IMM-101 prime for increased clinical responses to checkpoint inhibitors in metastatic melanoma and pancreatic cancer? Poster presented at the Annual Meeting of SITC, held at National Harbour, Maryland (USA) 9-13 November 2016.

2016

Crooks J, Brown S, Rosa Brunet L, MacDonald A. The impact of Mycobacterium obuense (NCTC13365) on innate and adaptive immunity. Poster presented at the Keystone Symposium “Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies” held in Vancouver (Canada) 24-28 January 2016.

2015

Dalgleish A and Stebbing J (2015). Five-year survival in patients with metastatic melanoma receiving IMM-101. Poster presented at the ESMO Immuno Oncology meeting in Lugano (Switzerland) 20-21 November 2015 and published in Annals of Oncology 2015; 26:viii5.

2015

Brunet LR, Bodman-Smith K, Bodman-Smith M et al. Identification of circulatory biomarkers from clinical trial samples. Poster presented at the Annual Meeting of SITC, held at National Harbour, Maryland (USA) 4-8 November 2015 and published in Journal for ImmunoTherapy of Cancer 3(Suppl 2):P104.

2015

Dalgleish AG and the IMAGE 1 Trial Investigators. IMM-101 extends survival and maintains quality of life in IMAGE 1, a randomized, open-label, phase 2 trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. Poster presented at the ESMO World Congress on Gastrointestinal Cancer held in Barcelona (Spain) 1 – 4 July 2015.

2015

Dalgleish AG and the IMAGE 1 Trial Investigators. Long-term survival in IMAGE 1: A multi-center randomised, open-label, proof-of-concept phase 2 trial comparing Gemcitabine with and without IMM-101 in advanced pancreatic cancer. Poster presentated at the ASCO Annual Meeting held in Chicago (US) 29 May – 2 June 2015.

2014

Bilyard H, Mines C, Brunet LR et al. IMM-101, an investigational immunotherapeutic product in clinical development as an adjunctive treatment for pancreatic cancer. Poster Presentation at the Annual Meeting of SITC held at National Harbour, Maryland (USA) 6-9 November 2014.

2014

Fowler DW, Dalgleish AG and Liu WM. A heat-killed preparation of Mycobacterium obuense can reduce metastatic burden in vivo. Poster Presentation at the Annual Meeting of SITC held at National Harbour, Maryland (USA) 6-9 November 2014 and published in Journal for ImmunoTherapy of Cancer 2014; 2(Suppl 3):P54.

2013

Elia A, Mapes J, Knorpp T et al. A role for immunotherapy: preventing macrophage anergy in the tumour environment. Poster Presentation at the Annual Meeting of SITC held at National Harbour, Maryland (USA) 8-10 November, 2013 and published in Journal for ImmunoTherapy of Cancer 2013 1(Suppl 1):P185.

2013

Elia A, Lincoln L, Brunet L, Hagemann T. Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer. Poster Presentation at the Annual Meeting of SITC held at National Harbour, Maryland (USA) 8-10 November 2013 and published in Journal for ImmunoTherapy of Cancer 2013; 1(Suppl 1):P215.

2013

Elia A, Garcia E & Brunet L. The Immunosuppresive effect of Pancreatic cancer Supernatant on Macrophages; A Modulatory Role for IMM- 101. Poster Presentation at the Roche Forum – Nature Medicine Immunology Symposium 2013; Host Immunity to Cancer and Chronic Viral Infections, presented at Roche Forum, in Switzerland, on 28-30th April 2013.